Drug Profile
Research programme: fatty acid amide hydrolase inhibitors - Johnson & Johnson
Alternative Names: JNJ 28833155; JNJ-1661010Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Amides; Piperazines; Small molecules; Thiadiazoles
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 26 Aug 2010 Preclinical development is ongoing in the US
- 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Neuropathic pain presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008)